Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
収録刊行物
-
- The Lancet Haematology
-
The Lancet Haematology 8 (1), e45-e54, 2021-01
Elsevier BV